Vaxcyte, Inc. PCVX Investment Proceeds
Investment Proceeds at other companies
Other financials
Where this comes from
Reported directly by Vaxcyte, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt.
The official record: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vaxcyte, Inc.'s investment proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vaxcyte, Inc.'s investment proceeds?
- Vaxcyte, Inc. (PCVX) reported investment proceeds of $24.88M in Q1 2026.
- How has Vaxcyte, Inc.'s investment proceeds changed year-over-year?
- Vaxcyte, Inc.'s investment proceeds decreased by 4.5% year-over-year, from $26.07M to $24.88M.
- What is the long-term trend for Vaxcyte, Inc.'s investment proceeds?
- Over 3 years (2022 to 2025), Vaxcyte, Inc.'s investment proceeds has grown at a 129.4% compound annual growth rate (CAGR), from $14.48M to $174.69M.
- What does investment proceeds mean?
- Cash received from sales, maturities, and redemptions of investment securities across all categories.